

## SynAct Pharma to attend BIO-Europe in Stockholm November 4-6

**SynAct Pharma AB ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, today announces the company plans to attend BIO-Europe in Stockholm from November 4-6.**

SynAct's management team is attending the partnering event to discuss the company's ongoing Phase 2b ADVANCE clinical trial studying its lead drug candidate resomelagon (AP1 189) in patients with newly diagnosed severe rheumatoid arthritis.

### **About BIO-Europe**

BIO-Europe is one of the largest partnering events in Europe, bringing together more than 5,500 delegates to participate in over 30,000 one-to-one meetings, and is a key platform connecting the global biopharma community.

### **For further information, please contact:**

Jeppé Øvlesen

CEO, SynAct Pharma AB

Phone: + 45 2844 7567

E-mail: [investor.relations@synactpharma.com](mailto:investor.relations@synactpharma.com)

### **About SynAct Pharma AB**

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: [www.synactpharma.com](http://www.synactpharma.com).

### **Attachments**

[SynAct Pharma to attend BIO-Europe in Stockholm November 4-6](#)